Related Experiment Video

Updated: May 10, 2026

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
08:57

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Genomic and molecular aberrations in malignant peripheral nerve sheath tumor and their roles in personalized target

Jilong Yang1, Xiaoling Du

  • 1Departments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Hospital and Institute, Tianjin 30060, China. jilongyang@yahoo.com

Surgical Oncology
|July 9, 2013
PubMed

Insights

Malignant peripheral nerve sheath tumors (MPNSTs) have poor outcomes, necessitating new treatments. Genomic analysis reveals specific gene and pathway alterations, offering potential targets for personalized MPNST therapy.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive cancers with high recurrence and metastasis rates.
  • Current therapeutic strategies for MPNSTs are limited, highlighting the need for novel treatment approaches.
  • Understanding the genomic landscape of MPNSTs is crucial for developing targeted therapies and personalized medicine.

Purpose of the Study:

  • To investigate the genomic and molecular aberrations in Malignant Peripheral Nerve Sheath Tumors (MPNSTs).
  • To identify potential therapeutic targets for MPNSTs based on identified genetic alterations.
  • To explore the role of specific signaling pathways in MPNST development and progression.

Main Methods:

  • Comprehensive analysis of chromosomal aberrations, including gene gains and deletions, in MPNSTs.
  • Identification of frequently altered genes and their involvement in key signaling pathways.
  • Evaluation of specific molecular targets for their therapeutic potential in MPNSTs.

Main Results:

  • Significant gene gains were observed for BIRC5, CCNE2, EGFR, CDK6, MET, and PDGFRA, among others.
  • Significant gene deletions were identified for CDH1, TP53, and p16/INK4a, among others.
  • Aberrations in TFF, EGFR, ARF, and IGF1R signaling pathways were implicated in MPNSTs.

Conclusions:

  • Genomic and molecular aberrations in MPNSTs provide numerous potential therapeutic targets.
  • Specific genes such as EGFR, IGF1R, SOX9, EYA4, TOP2A, ETV4, and BIRC5 show promise for personalized MPNST treatment.
  • Further research into these targets could lead to improved therapeutic strategies for MPNST patients.
Keywords:
Genetic aberrationMalignant peripheral nerve sheath tumorMicroarray-based comparative genomic hybridizationPersonalized medicineTarget therapy

More Related Videos

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...